Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Response to chemotherapy is not related to chromosome instability in synovial sarcoma.

Chakiba C, Lagarde P, Pissaloux D, Neuville A, Brulard C, Pérot G, Coindre JM, Terrier P, Ranchere-Vince D, Ferrari A, Collini P, Suurmeijer AJ, Blay JY, Terrisse SA, Piperno-Neumann S, Averous G, Bui B, Orbach D, Italiano A, Chibon F.

Ann Oncol. 2014 Nov;25(11):2267-71. doi: 10.1093/annonc/mdu362. Epub 2014 Jul 28.

2.

Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.

Lagarde P, Przybyl J, Brulard C, Pérot G, Pierron G, Delattre O, Sciot R, Wozniak A, Schöffski P, Terrier P, Neuville A, Coindre JM, Italiano A, Orbach D, Debiec-Rychter M, Chibon F.

J Clin Oncol. 2013 Feb 10;31(5):608-15. doi: 10.1200/JCO.2012.46.0147. Epub 2013 Jan 14.

PMID:
23319690
3.

Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features.

Przybyl J, Sciot R, Wozniak A, Schöffski P, Vanspauwen V, Samson I, Siedlecki JA, Rutkowski P, Debiec-Rychter M.

Int J Biochem Cell Biol. 2014 Aug;53:505-13. doi: 10.1016/j.biocel.2014.05.006. Epub 2014 May 16.

PMID:
24842110
4.

Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma.

Wu Y, Bi W, Han G, Jia J, Xu M.

World J Surg Oncol. 2017 May 11;15(1):101. doi: 10.1186/s12957-017-1165-9.

5.

Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.

Salah S, Yaser S, Salem A, Al Mousa A, Abu Sheikha A, Sultan I.

Med Oncol. 2013;30(3):639. doi: 10.1007/s12032-013-0639-z. Epub 2013 Jun 19.

PMID:
23780657
6.

Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.

Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM.

J Clin Oncol. 2000 Nov 15;18(22):3794-803.

PMID:
11078492
7.

Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.

Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS.

Cancer. 1994 May 15;73(10):2506-11.

PMID:
8174046
8.

Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.

Ates O, Aksoy S, Yeter H, Sunar V, Kertmen N, Dizdar O, Turker A, Kars A.

Indian J Cancer. 2017 Jan-Mar;54(1):321-325. doi: 10.4103/ijc.IJC_169_17.

9.

Synovial sarcoma relapses in children and adolescents: prognostic factors, treatment, and outcome.

Soole F, Maupain C, Defachelles AS, Taque S, Minard-Colin V, Bergeron C, De Rycke Y, Orbach D.

Pediatr Blood Cancer. 2014 Aug;61(8):1387-93. doi: 10.1002/pbc.25001. Epub 2014 Mar 24.

PMID:
24664883
10.

Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.

Spurrell EL, Fisher C, Thomas JM, Judson IR.

Ann Oncol. 2005 Mar;16(3):437-44. Epub 2005 Jan 14.

PMID:
15653701
11.

A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients.

Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S.

Clin Cancer Res. 2008 Dec 15;14(24):8191-7. doi: 10.1158/1078-0432.CCR-08-0843.

12.

Synovial sarcoma. A Scandinavian Sarcoma Group project.

Skytting B.

Acta Orthop Scand Suppl. 2000 Apr;291:1-28.

PMID:
10862210
13.

Synovial sarcoma involving skull base--a retrospective analysis of diagnosis and treatment of 21 cases in one institution.

Ji T, Ma CY, Ow A, Wang LZ, Sun J, Zhang CP.

Oral Oncol. 2011 Jul;47(7):671-6. doi: 10.1016/j.oraloncology.2011.04.014. Epub 2011 Jun 8.

PMID:
21641853
14.

Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension.

Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM.

Head Neck. 2007 Aug;29(8):731-40.

PMID:
17274049
15.

Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.

Chen Y, Yang Y, Wang C, Shi Y.

J Surg Oncol. 2012 Aug 1;106(2):162-8. doi: 10.1002/jso.23061. Epub 2012 Feb 1.

PMID:
22297839
16.

[Evaluation of prognostic factors for synovial sarcoma].

Du ZY, Guo W, Yang RL, Yan TQ, Li DS.

Zhonghua Wai Ke Za Zhi. 2011 Nov;49(11):991-4. Chinese.

PMID:
22333419
17.

Intravascular synovial sarcoma of the pulmonary artery with massive pleural effusion: report of a case with a favorable response to Ifosfamide chemotherapy and palliative radiation therapy.

Maekura T, Shimizu S, Kawaguchi T, Morimoto M, Okuma T, Matsui H, Atagi S.

Intern Med. 2015;54(9):1095-8. doi: 10.2169/internalmedicine.54.3624. Epub 2015 May 1.

18.

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.

Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG.

Cancer. 2004 Aug 1;101(3):627-34.

19.

Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance.

Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, Solheim OP, Sobrinho-Simões M, Nesland JM.

Pathol Res Pract. 1997;193(1):21-36.

PMID:
9112270
20.

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

Italiano A, Penel N, Robin YM, Bui B, Le Cesne A, Piperno-Neumann S, Tubiana-Hulin M, Bompas E, Chevreau C, Isambert N, Leyvraz S, du Chatelard PP, Thyss A, Coindre JM, Blay JY.

Ann Oncol. 2009 Mar;20(3):425-30. doi: 10.1093/annonc/mdn678. Epub 2008 Dec 16.

PMID:
19088169

Supplemental Content

Support Center